Age versus clinical virological characteristics in chronic hepatitis B virus infection: A case series study in China

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 4, 2012, Pages 406-413

  Wu, Dian Lei ^a,b   Xu, Guang Hua ^b   Lu, She Min ^a   Ma, Bo Lin ^b   Miao, Nai Zhou ^b   Liu, Xiao Bin ^b   Feng, Ji Hong ^b   Liu, Na ^b   Zeng, Qing Lei ^b   Hou, Wei Kun ^a   Pei, Lei ^a   Zhao, Yingren ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b YAN'AN UNIVERSITY   (China)

Author keywords

Age; Chronic hepatitis b virus infection; Clinical virology; Immune clearance; Reactivation

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE STUDY; CHINA; DNA CONTENT; FEMALE; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SEROCONVERSION; VIRAL CLEARANCE; VIRUS CHARACTERIZATION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGE FACTORS; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; MALE; MIDDLE AGED; RECURRENCE; SEX FACTORS; TIME FACTORS; VIRAL LOAD; VIRUS ACTIVATION; VIRUS REPLICATION; YOUNG ADULT;

EID: 84859314021     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834fbf35     Document Type: Article

References (42)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107. (Pubitemid 38365759)
2. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346:1682-1683.
3. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2:395-403.
4. Lin CL, Liao LY, Liu CJ, Yu MW, Chen PJ, Lai MY, et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum anine aminotransferase levels. Hepatology 2007; 45:1193-1198.
5. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
6. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
7. Liu J, Li Y, Chen T, Yang Y, Wang K, He Y, et al. The distribution of HBV genotypes and clinical significance in familial clustering in an infected population with unfavorable prognosis. Arch Virol 2008; 153:2157-2161.
8. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124:327-334.
9. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13:29-60.
10. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84:216-219. (Pubitemid 13224257)
11. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92:1839-1843. (Pubitemid 17072230)
12. Fung SK, Lok AS. Treatment of chronic hepatitis B: who to treat, what to use, and for how long? Clin Gastroenterol Hepatol 2004; 2:839-848. (Pubitemid 39335789)
13. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J infect Dis 1997; 175:674-677. (Pubitemid 27086173)
14. Iwarson S. Strategies for immunization against hepatitis B in western Europe. Vaccine 1993; 11:18-20.
15. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2:1099-1102. (Pubitemid 14242389)
16. Zanetti AR, Mariano A, Romano L, Damelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379-1384. (Pubitemid 41443405)
17. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54:1-31.
18. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on hepatitis B virus and cirrhosis. Hepatology 1995; 21:77-82.
19. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. New Engl J Med 1996; 334:1422-1427. (Pubitemid 26157437)
20. De Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver.. Gastroenterology 1992; 103:1630-1635.
21. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145:1039-1047.
22. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32:294-298.
23. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26:1338-1342. (Pubitemid 27509322)
24. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29:971-975.
25. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113:1660-1667. (Pubitemid 27461254)
26. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
27. Villa E, Rubbiani L, Barchi T, Ferretti I, Grisendi A, De Palma M, et al. Susceptibility of chronic symptomless HBsAg carriers to ethanol induced hepatic damage. Lancet 1982; 2:1243-1244.
28. Chevillotte G, Durbec JP, Gerolami A, Berthezene P, Bidart JM, Camatte R. Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis: an epidemiologic study. Gastroenterology 1983; 85:141-145. (Pubitemid 13106335)
29. Sung JJ, Chan HL, Wong ML, Tse CH, Yuen SC, Tam JS, et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepatol 2002; 9:229-234. (Pubitemid 36005522)
30. Lok ASF. Should antiviral treatment Be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? Hepatology 2010; 51:1107-1109.
31. Lin CL, Liao LY, Wang CS, Chen PJ, Lai MY, Chen DS, et al. Basal core promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int 2005; 25:564-570.
32. Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006; 193:1258-1265.
33. Liu CJ, Chen BF, Chen PJ, Lai MY, HuangWL, Kao JH, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case control study. J Infect Dis 2006; 194:594-599.
34. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130:1153-1168.
35. Gaeta GB, Stornaiuolo G, Precone DF, Lobello S, Chiaramonte M, Stroffolini T, et al. Epidemiological and clinical burden of chronic hepatitis B Virus/hepatitis C virus infection. A nulticenter Italian study. J Hepatol 2003; 39:1036-1041. (Pubitemid 37523777)
36. Milich DR, Schodiel F, Hughes JL, Jones JE, Peterson DL. The hepatitis B virus and e antigen structure can affect Th cell phenotype. J Virol 1997; 71:2192-2201.
37. Petit MA, Zoulim F, Capel F, Dubanchet S, Dauguet C, Trepo C. Variable expression of preS1 antigen in serum during chronic hepatitis B virus replication: an acute marker for the level of hepatitis B virus replication. Hepatology 1990; 11:809-814. (Pubitemid 20191387)
38. Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53:1494-1498. (Pubitemid 39265273)
39. Chu CJ, Hussain M, Lok ASF. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122:1756-1762. (Pubitemid 34651418)
40. Orito EM, Mizokami H, Sakugawa K, Michitaka K, Ishikawa T, Ichida T, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Hepatology 2001; 33:218-223. (Pubitemid 32016905)
41. Sumi HO, Yokosuka N, Seki M, Arai F, Imazeki T. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37:19-26.
42. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49 (5 Suppl):S45-S55.